Biotronik Japan announced enrollment of the first patient in the Bioflow-IV study, which aims to verify the efficacy and safety of the Orsiro Hybrid Drug-Eluting Stent (DES) from Biotronik.

The American Society of Echocardiography (ASE) Foundation is announced the Echo AUC, a new mobile application that is designed to guide physicians in appropriate procedures in cardiovascular care and echocardiography, is available for download in both the Apple and Droid application stores.

Alivecor Inc. announced that the AliveCor Heart Monitor is now being offered to participants in the Health eHeart Study with 2,000 units to be deployed before the end of the year. 

Researchers at The University of Texas Health Science Center at Houston (UTHealth) led a study that showed that a hands-free ultrasound device, combined with a clot-busting drug, was safe for ischemic stroke patients.

Biosensors International’s expanded product portfolio offers physicians a broader range of treatment options to improve patient outcomes.

Simbionix, a provider of innovative training solutions, announced the initiation of the REHEARSAAAL study which evaluates the clinical benefits of preoperative patient specific simulation using the PROcedure Rehearsal Studio for the treatment of Abdominal Aortic Aneurysms (AAAs) by Endovascular Aortic Repair (EVAR). A multidisciplinary group of physicians from vascular surgery, interventional radiology and cardiology departments in hospitals across the United States and Europe will conduct the study.

CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education and advancement of medical technologies, will present data from the podium at the Transcatheter Cardiovascular Therapeutics annual scientific meeting (TCT 2013) that provides a seminal experimental and computational template for a more rational, comprehensive preclinical evaluation and optimization of renal denervation devices.

A new valve recently approved by the U.S. Food and Drug Administration (FDA) now gives heart patients a new way to manage their disease without having to undergo open heart surgery.?

The Cardiovascular Research Foundation (CRF) announced the appointment of John (Jack) Lewin, M.D., as the foundation’s president and CEO.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now